OKE
61
2
BLK
47
3
BAX
38
2
MAS
46
3
EFX
43
3
STT
48
4
CCL
68
6
CTSH
55
3
WHR
61
3
MPC
28
3
CF
47
5
CPB
24
2
KSS
36
2
NRG
32
5
AAL
56
5
LRCX
56
4
SYK
50
4
AMT
30
2
EA
41
3
TROW
37
8
OKE
61
2
BLK
47
3
BAX
38
2
MAS
46
3
EFX
43
3
STT
48
4
CCL
68
6
CTSH
55
3
WHR
61
3
MPC
28
3
CF
47
5
CPB
24
2
KSS
36
2
NRG
32
5
AAL
56
5
LRCX
56
4
SYK
50
4
AMT
30
2
EA
41
3
TROW
37
8
Financhill
Back

Spero Therapeutics 10K Form

Sell
8

SPRO
Spero Therapeutics

Last Price:
$0.92
Seasonality Move:
10.44%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive SPRO News And Ratings

See the #1 stock for the next 7 days that we like better than SPRO

SPRO Financial Statistics

Sales & Book Value

Annual Sales: $96.7M
Cash Flow: $12.8M
Price / Cash Flow: 0
Annual Sales: $1.21
Price / Book: 0.8

Profitability

EPS (TTM): 0.08000
Net Income (TTM): $3.5M
Gross Margin: $7.4M
Return on Equity: 4.36%
Return on Assets: 2.37%

Spero Therapeutics Earnings Forecast

Key Spero Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 10 years for SPRO is 54.81%.
  • The Selling, General & Administrative Expenses for SPRO have been equal to 26.42% of Gross Profit Margin.
  • The Research & Development expenses have been 53.18% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of SPRO is 23.58% of Total Revenues.
  • Per Share Earnings over the last 19 years have been positive in 8 years.

Spero Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: SPRO
CUSIP: 84833T
Website: sperotherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 2.68
Quick Ratio: 2.64

Price-to-Earnings

Trailing P/E Ratio: 2.23
Forward P/E Ratio: 0

SPRO Technical Analysis vs Fundamental Analysis

Sell
8
Spero Therapeutics (SPRO) is a Sell

Is Spero Therapeutics a Buy or a Sell?